Henan Lingrui Pharmaceutical's earnings growth, likely thanks to its high ROE, is admirable. Its ability to raise earnings while paying out most profits as dividends is notable. Continued growth is expected by analysts.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more